View Older Stories View More Recent Stories

Dec 4, 2019 08:00AM Advaxis to Present at 12th Annual LD Micro Main Event Investor Conference
Dec 3, 2019 08:02AM Advaxis (ADXS) Reports Submission of IND Application for ADXS-HOT Drug Candidate for Prostate Cancer
Dec 3, 2019 08:00AM Advaxis Announces Submission of IND Application for ADXS-HOT Drug Candidate for Prostate Cancer
Oct 24, 2019 09:00AM Advaxis Announces Business and Pipeline Update
Oct 10, 2019 08:09AM Advaxis (ADXS), UCLA Enter Collaboration for Glioblastoma Immunotherapy Discovery Research
Oct 10, 2019 08:00AM Advaxis and UCLA Enter Collaboration for Glioblastoma Immunotherapy Discovery Research
Oct 7, 2019 08:02AM Advaxis (ADXS) Reports Updated Prolonged Survival Data in Phase 1/2 ADXS-PSA Trial
Oct 7, 2019 08:00AM Advaxis Announces Updated Prolonged Survival Data in Phase 1/2 ADXS-PSA Trial
Sep 9, 2019 08:00AM Advaxis Reports Fiscal Third Quarter 2019 Financial Results and Provides Pipeline Update
Jul 15, 2019 08:02AM Advaxis (ADXS) Reports New Immune Data from Ongoing ADXS-NEO Phase 1 Study Support Clinical Potential for Neoantigen-Directed Immunotherapies
Jul 15, 2019 08:00AM New Immune Data from Ongoing ADXS-NEO Phase 1 Study Support Clinical Potential for Neoantigen-Directed Immunotherapies
Jun 27, 2019 06:53AM Advaxis (ADXS) Announces Increasing Focus on Neoantigen-Directed Immunotherapies, Reports Closing of Its Phase 3 AIM2CERV Study
Jun 27, 2019 06:50AM Advaxis Announces Increasing Focus on Neoantigen-Directed Immunotherapies and Closing of Its Phase 3 AIM2CERV Study
Jun 10, 2019 04:05PM Advaxis Reports Second Quarter Fiscal 2019 Financial Results and Provides Pipeline Update
Jun 4, 2019 08:00AM Advaxis to Host Business Update Conference Call on June 11, 2019
May 15, 2019 08:03AM Advaxis (ADXS) Announces FDA Lifts Partial Clinical Hold on Phase 3 AIM2CERV Study of Axalimogene Filolisbac
May 15, 2019 08:00AM FDA Lifts Partial Clinical Hold on Phase 3 AIM2CERV Study of Axalimogene Filolisbac
May 14, 2019 09:00AM Advaxis Announces Two Poster Presentations at the Frontiers in Cancer Immunotherapy Conference
May 13, 2019 03:00PM Advaxis Announces Appointment of Dr. Robert Petit to Chair of Scientific Advisory Board and Departure as Chief Scientific Officer
May 7, 2019 09:00AM Advaxis to Participate in Five Upcoming Industry Conferences
Apr 1, 2019 08:03AM Advaxis (ADXS) ADXS-PSA in Combination with KEYTRUDA Prolonged Survival in mCRPC
Apr 1, 2019 08:00AM ADXS-PSA in Combination with KEYTRUDA® Prolonged Survival in Metastatic Castration-Resistant Prostate Cancer
Mar 29, 2019 03:01PM Advaxis (ADXS) Preliminary Data from Phase 1 Study Evaluating ADXS-NEO Suggest Rapid Immunogenicity and Clinical Activity
Mar 29, 2019 03:00PM Preliminary Data from Phase 1 Study Evaluating ADXS-NEO Suggest Rapid Immunogenicity and Clinical Activity
Mar 28, 2019 01:03PM Advaxis (ADXS) Reports 1-for-15 Reverse Share Split
Mar 28, 2019 01:00PM Advaxis Announces Reverse Stock Split
Mar 25, 2019 08:04AM Advaxis (ADXS) Granted U.S. Patent Relating to Axalimogene Filolisbac
Mar 25, 2019 08:00AM Advaxis Granted U.S. Patent Relating to Axalimogene Filolisbac
Mar 12, 2019 08:00AM Advaxis Reports First Quarter Fiscal 2019 Financial Results and Provides Clinical Pipeline Update
Mar 11, 2019 08:00AM Advaxis Announces Presentations of ADXS-NEO and ADXS-PSA Data at Upcoming American Association for Cancer Research Annual Meeting
Feb 14, 2019 08:31AM Advaxis (ADXS) Reports First Patient Enrollment in Phase 1/2 Trial for ADXS-HOT in the Treatment of NSCLC
Feb 14, 2019 08:30AM Advaxis Announces Enrollment of the First Patient in its Phase 1/2 Trial for ADXS-HOT in the Treatment of Non-Small Cell Lung Cancer
Feb 6, 2019 08:30AM Advaxis Presents an Overview of its Lm Platform and Neoantigen-Directed Programs at the Immuno-Oncology 360° Conference
Jan 28, 2019 08:05AM Advaxis to Present an Overview of its Lm Platform and New Information on its Neoantigen-Directed Therapy Programs at the Immuno-Oncology 360° Conference
Jan 25, 2019 08:05AM Data Highlighting Potential Benefits of Lm Platform Presented at 2019 Keystone Symposia Conference on Cancer Vaccines
Jan 23, 2019 04:07PM Advaxis (ADXS) Says Phase 3 AIM2CERV Study Placed on Partial Clinical Hold by FDA Related to CMC Requests ADXS: Advaxis
Jan 23, 2019 04:05PM Advaxis’ Phase 3 AIM2CERV Study Placed on Partial Clinical Hold by FDA Related to CMC Requests
Jan 10, 2019 04:05PM Advaxis Reports Fiscal Year 2018 Financial Results and Provides a Business Update
Jan 8, 2019 08:00AM Advaxis to Host Business Update Conference Call on January 15, 2019
Nov 28, 2018 08:00AM Advaxis to Present at LD Micro Main Event
Nov 6, 2018 08:00AM Advaxis to Present Poster Entitled “Natural Killer (NK) Cells Orchestrate the Antitumor Activities of Listeria monocytogenes (Lm)-Based Immunotherapy” at Society for Immunotherapy of Cancer Annual
Nov 2, 2018 08:04AM Advaxis (ADXS) Announces Update on Clinical Pipeline
Nov 2, 2018 08:00AM Advaxis Provides Update on Clinical Pipeline
Oct 26, 2018 08:00AM Advaxis to Host Business Update Conference Call on November 2, 2018
Sep 10, 2018 04:30PM Advaxis Reports Fiscal 2018 Third Quarter Business Highlights and Financial Results
Sep 4, 2018 08:49AM Advaxis (ADXS) Gains on ADXS31-164 License to OS Therapies
Sep 4, 2018 08:00AM Advaxis Licenses ADXS-HER2 to OS Therapies for Evaluation in the Treatment of Osteosarcoma
Jul 30, 2018 08:07AM Advaxis (ADXS) Announces FDA Allowance of IND Application for ADXS-HOT Drug Candidate for NSCLC
Jul 30, 2018 08:00AM Advaxis Announces FDA Allowance of IND Application for ADXS-HOT Drug Candidate for Non-Small Cell Lung Cancer
Jul 13, 2018 08:03AM Advaxis (ADXS) Reports FDA Lift of Clinical Hold on Phase 1/2 Combination Study of Axalimogene Filolisbac with Durvalumab
View More Recent Stories View Older Stories